High-Level Forum on Lung Health
February 26, 2026
On 24 February 2026, the European Lung Health Group (ELHG) convened its second High-Level Forum on Lung Health in Brussels.
On 24 February 2026, the European Lung Health Group (ELHG) convened its second High-Level Forum on Lung Health in Brussels.
The European Patients’ Forum (EPF) is an independent, non-profit umbrella organisation representing 78 patient organisations across Europe, encompassing various disease areas and national coalitions.
The ERS Congress 2024 in Vienna attracted close to 20,000 delegates, both onsite and online, making it a vibrant and dynamic event focused on advancing
PHA Europe is pleased to share the exciting news that the European Medicines Agency (EMA) has approved WINREVAIR™ (sotatercept) for the treatment of Pulmonary Arterial
PHA recently held its 15th international PH conference in Indianapolis, Indiana. This gathering brought together a diverse group of about 1100 healthcare professionals, researchers, patients,
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the
The Saudi Association for Pulmonary Hypertension (SAPH) hosted its 17th annual conference in Riyadh, Saudi Arabia, from February 15 to 17, 2024. The conference featured
Ferrer annually hosts a conference known as IMPACHT (International Meeting on Pulmonary Hypertension Clinical Treatment) that caters to pulmonologists and cardiologists.
The EU Commission invite stakeholders to a meeting to discussed the revision of the pharmaceutical legislation. The general director of SG SANTE lead the meeting.
European Patients’ Forum turned 20 years in 2023. This was marked with an event in Brussels where members, industry and others were invited. (PHA Europe
Dear Friends, Colleagues and Supporters, It is always a great pleasure to look back and see the ample accomplishments of the past year. From the
Three new drugs for pulmonary hypertension have been approved by the US and/or EU regulatory authorities in the course of the last year: